Rituximab in refractory Wegener's granulomatosis: Favorable or not? [4]

American Journal of Respiratory and Critical Care Medicine

Volumn 173, Issue 7, 2006, Pages 816-

  Keogh, Karina A ^a   Fervenza, Fernando C ^a   Specks, Ulrich ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; RITUXIMAB;

CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; INFLAMMATION; LETTER; LUNG NODULE; LYMPHOMA; MICROSCOPIC POLYANGIITIS; PRIORITY JOURNAL; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 33645309051     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/ajrccm.173.7.816     Document Type: Letter

References (4)

1. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006;173:180-187.
2. Aries PM, Hellmich B, Both M, Nolle B, Voswinkel J, Holl-Ulrich K, Lamprecht P, Gross WL. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis (In press)
3. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:262-268.
4. Maloney DG, Grillo-Lopez AJ,White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-2195.